k.fontaine96/100
Purity by RP-HPLC, wavelength stated, stability-indicating method named. Determination is reproducible from the certificate alone. Contributor declares no interest beyond the transaction.
WXT — WuXi TIDES (WuXi AppTec Testing Division)
Wuxi, CN · established 2002. The index holds 301 assay reports across 51 batches and 26 compounds, contributed by 6 laboratories. Every figure below is computed from those records and from nothing else.
Where WXT sells
WuXi TIDES (WuXi AppTec Testing Division) sells from its own storefront. The link is marked nofollow and sponsored: it exists so the figures on this scorecard can be read against what the supplier itself publishes. The index is paid nothing for it and a link is not an assessment.
Every figure above describes lots the index has seen. It says nothing about the lot you are offered, and the only check that does is the one on the certificate against the vial.
Block 1
Identification
Business facts, held constant across the index and not derived from the data. The index sells nothing and takes no supplier payment for placement; the storefront link below is marked nofollow and sponsored so a record can be checked against the seller, and is not a recommendation.
- Legal name
- WuXi TIDES (WuXi AppTec Testing Division)
- Short code in this index
- WXT
- Also known as
- WXT · WXT Biotech · WuXi TIDES (WuXi AppTec Testing Division)
- Domain
- wuxitides.net →
- City
- Wuxi
- Region
- Wuxi
- Country
- CN
- Established
- 2002
- First record in index
- 10 Jan 2024
- Most recent record
- 15 Oct 2026
Block 1b
Dispatch and regional stock
Counted from the chain-of-custody line on this supplier's own records, which names the route each vial travelled to the laboratory, and from the on-record reviews below. The index has no sight of any supplier's warehouse network and publishes none.
Domestic-warehouse route
14.3%
n=301
Retail, shipped to the buyer
64.1%
n=301
Direct to the laboratory
15.3%
n=301
Median courier leg, direct despatch
7d
n=46
| Route to the laboratory | Records | Share |
|---|---|---|
| Domestic warehouse despatch | 43 | 14.3% |
| Retail purchase, shipped to the buyer | 150 | 49.8% |
| Retail purchase via a third-party forwarder | 43 | 14.3% |
| Supplier despatch direct to the laboratory | 46 | 15.3% |
| Laboratory retained-sample archive | 19 | 6.3% |
Every record here carries a chain-of-custody line and that line names the route the vial travelled. Of the 301 WXT records the index holds, 43 reached the contributing laboratory from a domestic warehouse rather than as a cross-border consignment, covering 17 of the 26 compounds WXT is represented by here — Semaglutide, Tirzepatide, BPC-157, MOTS-c, PT-141 (Bremelanotide), CJC-1295 (no DAC) and 11 further compounds. Those are the WXT lines this index has actually seen arrive from regional stock, and they are a count of consignments rather than a stock listing: a line missing from them may simply never have been submitted for assay.
One contributor on the record below documents WXT stock held in Poland, with a transit of 6 working days against a quoted 6. Poland is the only regional stock location named anywhere in WXT's record here, and one consignment described by one buyer is exactly that. It is not a warehouse list and the index has not verified it.
The index measures nothing about lead time — it assays material, it does not buy it. What it has is WXT's own reviewers: 2 of the 26 on-record reviews state a quoted window and what happened against it, and 1 of them describes same-day dispatch. Where WXT despatched a sample direct to a laboratory, the courier leg ran a median 7 days across 46 such consignments — that is a transit time the index can see, and it is not the same thing as a lead time. The reviews are reproduced in full in Block 11.
Block 2
Headline statistics
Each figure carries the n it was computed from. The n= badge next to a statistic is the number of records it was computed from. Below n=8 the badge is amber. Below n=3 the statistic is suppressed and the individual values are shown instead.
Median purity
98.51%
n=301
Interquartile range
1.08pp
n=301
10th percentile
97.45%
n=301
Pass rate vs index spec
75.7%
n=301
Median recovery vs claim
97.5%
n=157
Median water
4.78%
n=301
Median |mass error|
2.4ppm
n=252
Records carrying a flag
27.9%
n=301
Block 3
Reproducibility across independent tests of one lot
Where the same physical lot was assayed more than once, the spread between those results is a property of the material and the fill, not of the market. It is the rarest and most informative statistic on this page, and it exists only for lots someone tested twice.
Median within-batch spread
1.00pp
n=38
Index median spread
0.67pp
n=28
Lots tested 3+ times
38
n=51
Across the 38 WXT lots in the index with three or more independent assays, the median spread between the highest and lowest purity result on one lot is 1.00 pp. Interpreting that number requires the laboratory repeatability figures: the best contributing laboratory here repeats to 0.16 pp and the worst to 0.34 pp, so a within-lot spread under about 0.5 pp is indistinguishable from measurement noise and a spread above 1 pp is a statement about the material.
Block 4
Supplier certificate against independent measurement
The supplier's own COA purity figure for a lot, minus the median of the index's independent observations of the same physical lot. Positive means the certificate reads higher than the measurement. Rule AX-R05 fires above 1.5 pp.
Median COA divergence
+0.10pp
n=51
Index median divergence
+0.06pp
n=28
Divergences in the supplier's favour
57%
n=51
Divergences beyond 1 pp
2%
n=51
Block 5
Provenance — where the tested material came from
Supplier-supplied samples are weaker evidence than independently purchased ones, because the supplier chose the vial. The index measures the size of that effect rather than assuming it.
Buyer-sourced median
98.43%
n=236
Supplier-supplied median
98.79%
n=46
Supplier-supplied share of records
15.3%
n=301
Block 6
Documentation completeness
The score is not an opinion about paperwork. Each component is the share of WXT batches in the index whose certificate carries that field, weighted as set out on the scoring rubric.
Documentation score
69/100
n=51
Index median score
85/100
n=28
| Certificate field | Batches carrying it | Rubric weight | |
|---|---|---|---|
| Purity figure stated | 100% | 25 points | |
| Analytical method stated (column, gradient, wavelength) | 61% | 25 points | |
| Peptide content stated | 59% | 20 points | |
| Endotoxin stated | 39% | 15 points | |
| Named impurities rather than a total | 23% | 15 points |
Block 7
Coverage by compound
The delta column is this supplier's median minus the index-wide median for the same compound, which is the only comparison worth making: comparing a supplier's aggregate against another supplier's aggregate compares their product mixes as much as their process control.
| Compound | Class | Reports | Median % | Index median % | Δ (pp) | Index spec | Pass % |
|---|---|---|---|---|---|---|---|
| Semaglutide | Incretin | 53 | 97.90 | 98.89 | -0.99 | 97.0 | 96 |
| BPC-157 | Tissue-repair | 34 | 98.67 | 99.16 | -0.49 | 98.0 | 79 |
| PT-141 (Bremelanotide) | Melanocortin-receptor | 27 | 98.69 | 99.38 | -0.69 | 98.5 | 67 |
| L-Glutathione (reduced) | Short | 24 | 98.07 | 99.33 | -1.26 | 98.5 | 21 |
| Tirzepatide | Incretin | 24 | 98.59 | 98.55 | +0.04 | 97.0 | 100 |
| MK-677 (Ibutamoren mesylate) | Non-peptide | 17 | 99.29 | 99.49 | -0.20 | 98.5 | 100 |
| MOTS-c | Metabolic | 13 | 98.46 | 99.13 | -0.67 | 98.0 | 62 |
| Leuprolide | Hypothalamic | 12 | 98.83 | 99.28 | -0.45 | 98.5 | 92 |
| CJC-1295 (no DAC) | Growth-hormone | 12 | 98.63 | 99.09 | -0.47 | 98.0 | 83 |
| GHRP-2 | Growth-hormone | 11 | 98.57 | 99.28 | -0.72 | 99.0 | 18 |
| Survodutide | Incretin | 10 | 97.87 | 98.38 | -0.51 | 96.5 | 100 |
| 5-Amino-1MQ | Non-peptide | 9 | 98.71 | 99.45 | -0.75 | 98.0 | 89 |
| CJC-1295 with DAC | Growth-hormone | 8 | 97.20 | 98.95 | -1.75 | 97.5 | 38 |
| N-Acetyl Semax Amide | Neuroactive | 7 n=7 | 98.40 | 99.35 | -0.95 | 98.5 | 43 |
| IGF-1 LR3 | Growth-hormone | 6 n=6 | 96.97 | 98.28 | -1.31 | 95.0 | 100 |
| TB-500 | Tissue-repair | 5 n=5 | 97.85 | 99.53 | -1.68 | 98.5 | 0 |
| Enclomiphene citrate | Non-peptide | 5 n=5 | 99.08 | 99.44 | -0.36 | 98.5 | 100 |
| GHRP-6 | Growth-hormone | 5 n=5 | 99.04 | 99.54 | -0.50 | 99.0 | 80 |
| Sermorelin | Growth-hormone | 4 n=4 | 98.94 | 99.06 | -0.12 | 98.0 | 75 |
| ARA-290 | Tissue-repair | 4 n=4 | 99.23 | 99.42 | -0.19 | 98.0 | 100 |
| Semax | Neuroactive | 4 n=4 | 98.69 | 99.46 | -0.77 | 98.5 | 100 |
| Tesamorelin | Growth-hormone | 2 n=2 | n<3 | 98.29 | — | 97.0 | 50 |
| Selank | Neuroactive | 2 n=2 | n<3 | 99.59 | — | 99.0 | 100 |
| Melanotan II | Melanocortin-receptor | 1 n=1 | n<3 | 99.42 | — | 98.5 | 100 |
| Liraglutide | Incretin | 1 n=1 | n<3 | 99.00 | — | 97.5 | 0 |
| Ipamorelin | Growth-hormone | 1 n=1 | n<3 | 99.47 | — | 99.0 | 100 |
Full per-compound breakdown with distributions and caveats →
Block 8
Quarterly trend
Submission volume is not market share and a quarterly median is not a trend unless the compound mix held still. Both caveats apply to every row below.
Median purity by quarter
Quarters with fewer than two purity records are gaps in the line rather than zeroes.
Coverage growth
Records added per quarter. Growth here is index coverage, not supplier volume.
| Quarter | Batches | Reports | Median purity | Range | Flagged |
|---|---|---|---|---|---|
| 2024-Q1 | 1 | 2 | n<3 | 97.76–97.85 | 1 |
| 2024-Q2 | 1 | 4 | 98.69 | 98.55–98.91 | 1 |
| 2024-Q3 | 3 | 20 | 98.85 | 97.35–99.79 | 2 |
| 2024-Q4 | 4 | 19 | 99.04 | 98.08–99.35 | 9 |
| 2025-Q1 | 6 | 39 | 98.55 | 96.83–99.72 | 10 |
| 2025-Q2 | 5 | 36 | 98.51 | 97.66–99.93 | 17 |
| 2025-Q3 | 9 | 47 | 98.91 | 96.78–99.80 | 10 |
| 2025-Q4 | 6 | 40 | 98.16 | 97.06–99.93 | 1 |
| 2026-Q1 | 5 | 19 | 98.38 | 97.17–99.17 | 6 |
| 2026-Q2 | 7 | 38 | 98.10 | 97.20–99.86 | 11 |
| 2026-Q3 | 4 | 37 | 97.97 | 96.58–99.41 | 16 |
Block 9
Which laboratory produced these numbers
Laboratories disagree with each other by a measured amount. A supplier tested mostly by one laboratory carries that laboratory's offset in its aggregate, and the adjusted column removes it.
| Laboratory | Reports | Median purity | Lab bias (pp) | Bias-adjusted |
|---|---|---|---|---|
| Janoshik | 140 | 98.45 | +0.00 | 98.45 |
| PeptideMeter | 45 | 98.55 | -0.05 | 98.60 |
| Medutest | 38 | 98.53 | +0.08 | 98.45 |
| VendorInvestigate | 33 | 98.19 | -0.11 | 98.30 |
| Nordanalyt | 27 | 98.55 | +0.02 | 98.53 |
| Kestrel | 18 | 98.78 | +0.24 | 98.54 |
Bias figures are estimated from paired same-lot comparisons and are published with their confidence intervals on inter-lab agreement.
Block 10
What this data does and does not show
Block 11
On-the-record reviews 26
Reviews are signed statements from index contributors about their own testing of this supplier's material. They are opinions attached to evidence, and they are not used in any statistic on this page.
89.0/ 1001,002 ratings across the index network
b.danquah95/100
Single lot identifier across the whole consignment. Intra-consignment comparison valid. Vial-to-vial mass variation under 2%.
d.restrepo99/100
Storage condition for the stability statement stated on the certificate. No further comment.
m.villalobos98/100
Blind submission of TB-500 5 mg to Medutest, origin withheld. 98.5% against 98.7% declared. Nothing unsecured in the consignment.
c.sobczak97/100
Published stock status matched availability. Same-day dispatch. Identifier matches across vial, certificate and commercial documentation.
k.guerrero100/100
Lot-specific certificate attached at despatch, issued against the code on the vial. Nothing needed requesting.
t.moreau95/100
Retention time assigned to the principal peak, printed.
m.kimani99/100
Water content by Karl Fischer, method named. Vial-to-vial mass variation under 2%.
la.haddad99/100
3 orders, 14 months. No substitution, no reformulation, no post-payment unavailability. Reorder at 18 months within 0.1 points of the original.
ch.dahlberg94/100
Certificate carries peptide content stated separately from purity. Complete against the index minimum data set at first issue. Nothing unsecured in the consignment. No adverse observation.
m.hartmann98/100
Labelling printed, lot and date legible on every unit examined. Independent verification of individual lots still required.
jo.lindholm99/100
Custom synthesis delivered 3 days inside the quoted schedule at the specified purity. Declared and independent figures differ by less than repeatability.
k.chowdhury95/100
Counter-ion identity and content answered quantitatively, one working day. Gradient and column chemistry stated.
r.wojcik96/100
Declared figure not adjusted upward between certificate and commercial documentation. Vial-to-vial mass variation under 2%.
a.chowdhury100/100
Twelve orders, water content on every certificate with the method stated. Contributor declares no interest beyond the transaction.
a.palacios95/100
Repeat determination at 10 months: 98.2%. Original: 98.2%. No drift detected in this sample.
s.kjaer96/100
Related-substances table itemised by impurity with assigned retention times. Not aggregated.
fe.novak97/100
Packing: the invoice sealed in its own sleeve rather than loose against the vials.
b.salinas96/100
Documentation complete at first issue. No supplementary request raised. Gradient and column chemistry stated.
j.ekstrom97/100
Lot WXT-25-287 submitted to PeptideMeter. Declared 97.4%, reported 97.7%. Delta inside method repeatability.
i.vogel97/100
Transit 6 days from stock held in Poland against a quoted 6. Customs documentation correct at first presentation.
bi.restrepo96/100
Orthogonal identity present: mass spectrometry alongside the chromatographic determination. n=1, declared as n=1.
v.rasmussen100/100
Tracking live from despatch and accurate at every scan. Documentation complete at first issue. Identifier matches across vial, certificate and commercial documentation.
el.mwangi98/100
Fill uniformity: 6 units weighed against declared fill, all within 2%. Declared and independent figures differ by less than repeatability. No adverse observation.
n.molnar96/100
Residual-solvent screen included unrequested. Gradient and column chemistry stated.
s.erdogan100/100
Every vial in the box sound on inspection: flange, crimp and cake. Vial-to-vial mass variation under 2%. Subsequent orders placed with the same supplier.
Block 12
Most recent records
Block 13
Contributor annotations on WXT records 509
Annotations are this index's only discussion surface: signed technical comments attached to a specific record by a named contributor. They are not moderated for agreement with the index's own arithmetic. The most recent on WXT material are below, each linked to the record it sits on.
A retail vial at 97.08 % is worth more evidentially than a selected vial at a higher figure. That is the whole argument for recording provenance at all.
Terminal-digit tests over a supplier's declarations are cheap and mostly inconclusive. Where they are conclusive, the conclusion is usually about document generation and not about laboratory practice.
Supplier-supplied records are under 7 % of the index and they cluster on compounds where independent submissions are rare. That correlation is worth knowing before pooling them.
A reference standard on the same sequence would upgrade this from a good mass to a traceable one. The distinction matters where a result is going to be cited rather than merely read.
The isotope pattern is consistent with the elemental composition of L-Glutathione (reduced). That is a second, independent check on identity and it agrees with the mass.
A retail vial at 99.16 % is worth more evidentially than a selected vial at a higher figure. That is the whole argument for recording provenance at all.
Aggregate content on a folded peptide is a stability-indicating parameter and reverse phase measures it badly. That is a method limitation rather than a material finding.
A cyclic peptide closed through an amide rather than a disulfide has none of these problems and a different set instead. The uncyclised precursor is the analogous species there.
Every annotation the index holds on WXT material sits on its own record; the full set is reachable from the record listing and from each contributor's page. To read them against what WXT itself publishes, open wuxitides.net → alongside.
Block 14
Where to buy WXT
WuXi TIDES (WuXi AppTec Testing Division) sells direct from wuxitides.net. Everything on this page describes lots the index has already seen; the certificate that matters is the one that arrives with the vial you order, and the lot code on it should match the vial. Ask for the lot-specific document rather than the batch-level summary, and ask for the integration report if you intend to reconcile the figure yourself.
Go to the WXT store at wuxitides.net →
Marked nofollow and sponsored. The index is paid nothing for it, takes no commission, and a link is not an assessment. Research compounds. Not medical advice. Nothing on this site is a safety assessment and nothing on it is approved for human use.